2,500 PDX *in vivo* tumor models with many in passage and available for efficacy testing.

**HuPrime** models are well-characterized and annotated with expression profiling (RNAseq and U219) and gene copy number (WES and SNP6) data. MicroRNA and hotspot analysis is also available.

- Large, diverse collection of PDX models from US, European, and Asian populations covering over 30 cancer types.
- Models derived from both treatment naive and pretreated patients.
- Many PDX derived from metastatic lesions.
- PDX models of both innate and acquired resistance.
- Constantly growing panels of PDX with patient-relevant mutations.
- Unique models of specific disease pathways for targeted therapy such as RET, ALK, EGFR, MET, IDH, RSPO, and HER2.
- Unique collections of rare disease models including TNBC, prostate cancer, and GIST.
- Curated, online, searchable database (**HuBase™**) of phenotypic and genotypic data, patient information, growth curves, and standard of care treatment data.